2008
DOI: 10.1073/pnas.0708960105
|View full text |Cite
|
Sign up to set email alerts
|

Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn

Abstract: The neonatal Fc receptor FcRn provides IgG molecules with their characteristically long half-lives in vivo by protecting them from intracellular catabolism and then returning them to the extracellular space. Other investigators have demonstrated that mice lacking FcRn are protected from induction of various autoimmune diseases, presumably because of the accelerated catabolism of pathogenic IgGs in the animals. Therefore, targeting FcRn with a specific inhibitor may represent a unique approach for the treatment… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

2
95
0
3

Year Published

2009
2009
2021
2021

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 93 publications
(100 citation statements)
references
References 38 publications
2
95
0
3
Order By: Relevance
“…In separate experiments, treatment of cynomolgus monkeys with rozanolixizumab did not affect IgM or IgA concentrations (data not shown), consistent with these molecules not being salvaged and recycled by FcRn, and with data reported by others on elimination of FcRn function (by a peptide antagonist; 19 in FcRn knockout mice 14 ). Generation of anti-drug antibodies (ADA) was detected in the majority of animals during the dosing period; however, no impact to PK or PD was observed.…”
Section: Resultssupporting
confidence: 87%
“…In separate experiments, treatment of cynomolgus monkeys with rozanolixizumab did not affect IgM or IgA concentrations (data not shown), consistent with these molecules not being salvaged and recycled by FcRn, and with data reported by others on elimination of FcRn function (by a peptide antagonist; 19 in FcRn knockout mice 14 ). Generation of anti-drug antibodies (ADA) was detected in the majority of animals during the dosing period; however, no impact to PK or PD was observed.…”
Section: Resultssupporting
confidence: 87%
“…Our group has focused on studying the effect of anti-FcRn peptides on IgG:FcRn interaction in vitro and their effects on IgG catabolism in vivo. Using peptide phage display screening, we discovered a consensus motif, Gly-His-Phe-Gly-Gly-X-Tyr, where X is preferably a hydrophobic amino acid (10). The motif is enclosed by a cysteine disulfide loop forming an 11-amino acid loop including the cysteines.…”
mentioning
confidence: 99%
“…The peptide was optimized (11,12) for inhibition of IgG binding to FcRn and stability in plasma, resulting in monomeric peptide SYN1327 (1) and dimeric peptide SYN1436 (2). Remarkably, peptide 2 was able to reduce the IgG concentrations in cynomolgus monkeys by up to 80% with repeated administration, and therefore may be a candidate for the treatment of humorally mediated autoimmune diseases (10).…”
mentioning
confidence: 99%
“…To inhibit human FcRn, we used a lysine analog of SYN1436 ( Figure 4A), 29 a peptide that binds with subnanomolar affinity to human FcRn, thus preventing IgG binding. 30 In vivo, SYN1436 reduces IgG levels in cynomolgus monkeys by 80%. 30 Serum anti-a3NC1 autoantibodies in FCRN-humanized mice treated with anti-FcRn peptide, but not with control peptide, sharply decreased to the same levels as in Fcrn 2/2 mice ( Figure 4B), and were no longer detected after 4 days.…”
mentioning
confidence: 99%
“…30 In vivo, SYN1436 reduces IgG levels in cynomolgus monkeys by 80%. 30 Serum anti-a3NC1 autoantibodies in FCRN-humanized mice treated with anti-FcRn peptide, but not with control peptide, sharply decreased to the same levels as in Fcrn 2/2 mice ( Figure 4B), and were no longer detected after 4 days. In mice, human IgG elicits murine antihuman IgG antibodies, forming ICs that …”
mentioning
confidence: 99%